Home / Uncategorized / Acorda Therapeutics crashes 40% after patients die in drug trial (ACOR)
acorda therapeutics stock price

Acorda Therapeutics crashes 40% after patients die in drug trial (ACOR)

  • Acorda Therapeutics, a drugmaker, plunged round 40% after patients died all the way through the corporate’s Parkinson’s illness drug trial, in step with Bloomberg’s Natasha Rausch.
  • Seven patients in the trial, which was once in the overall levels, advanced a serious an infection known as sepsis, and 5 died.
  • The corporate stated it could prevent including new patients to the trial.
  • It stated it has no speculation but for the way the patients died, however 4 of the patients that advanced sepsis additionally advanced a situation known as agranulocytosis, the place white-blood cells disappear from the frame, which can also be connected to the drug.
  • Shares had been up 50% for the 12 months prior to the drop on Wednesday.
  • Read Bloomberg’s complete tale right here.

CHECK OUT: Acorda’s are living inventory worth right here.

Join the dialog about this tale »

NOW WATCH: Why Amazon’s new headquarters sweepstakes makes it the ‘smartest corporate in the arena’


Check Also

Fintech Ecosystem – Financial Technology Research & Business Opportunities

BII This is a preview of a analysis document from Business Insider Intelligence, Business Insider’s …

Leave a Reply

Your email address will not be published. Required fields are marked *